{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:40:03Z","timestamp":1789555203146,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jchf.2024.11.020","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T19:33:59Z","timestamp":1742412839000},"page":"102380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Direct-to-Physician Marketing and Uptake of Optimal Medical Therapy for Heart Failure With Reduced Ejection Fraction"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0514-3193","authenticated-orcid":false,"given":"Colette","family":"DeJong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7612-3352","authenticated-orcid":false,"given":"Matthew S.","family":"Durstenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7090-5601","authenticated-orcid":false,"given":"Anubha","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Wen","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Adams","family":"Dudley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla Y.","family":"Hsue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruv S.","family":"Kazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jchf.2024.11.020_bib1","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.jacc.2021.02.006","article-title":"Quadruple medical therapy for heart failure","volume":"77","author":"Greene","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.jchf.2024.11.020_bib2","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1001\/jamacardio.2020.0898","article-title":"Association of optimal implementation of sodium-glucose cotransporter 2 inhibitor therapy with outcome for patients with heart failure","volume":"5","author":"Bassi","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"4","key":"10.1016\/j.jchf.2024.11.020_bib3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.jchf.2024.11.020_bib4","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.cardfail.2023.07.006","article-title":"Heart failure epidemiology and outcomes statistics: a report of the Heart Failure Society of America","volume":"29","author":"Bozkurt","year":"2023","journal-title":"J Card Fail"},{"issue":"1","key":"10.1016\/j.jchf.2024.11.020_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2022.08.009","article-title":"Heart failure drug treatment\u2014inertia, titration, and discontinuation","volume":"11","author":"Savarese","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"17","key":"10.1016\/j.jchf.2024.11.020_bib6","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.jchf.2024.11.020_bib7","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.jchf.2023.06.022","article-title":"Clinical inertia among outpatients with heart failure: application of treatment nonintensification taxonomy to EPIC-HF Trial","volume":"11","author":"Swat","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"8","key":"10.1016\/j.jchf.2024.11.020_bib8","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/jamacardio.2019.2276","article-title":"Impediments to implementing guideline-directed medical therapies","volume":"4","author":"Fonarow","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10.1016\/j.jchf.2024.11.020_bib9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jama.2018.19320","article-title":"Medical marketing in the United States, 1997-2016","volume":"321","author":"Schwartz","year":"2019","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.jchf.2024.11.020_bib10","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1001\/jamainternmed.2016.2765","article-title":"Pharmaceutical industry\u2013sponsored meals and physician prescribing patterns for Medicare beneficiaries","volume":"176","author":"DeJong","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"5","key":"10.1016\/j.jchf.2024.11.020_bib11","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.120.007521","article-title":"Association between industry marketing payments and prescriptions for PCSK9 (proprotein convertase subtilisin\/kexin type 9) inhibitors in the United States","volume":"14","author":"Inoue","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"7","key":"10.1016\/j.jchf.2024.11.020_bib12","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s11606-021-06980-6","article-title":"Associations between industry payments to physicians for antiplatelet drugs and utilization of cardiac procedures and stents","volume":"37","author":"Yanagisawa","year":"2022","journal-title":"J Gen Intern Med"},{"issue":"6","key":"10.1016\/j.jchf.2024.11.020_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003645","article-title":"Association between industry payments and prescriptions of long-acting insulin: an observational study with propensity score matching","volume":"18","author":"Inoue","year":"2021","journal-title":"PLoS Med"},{"issue":"9","key":"10.1016\/j.jchf.2024.11.020_bib14","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.2105\/AJPH.2017.303982","article-title":"Industry payments to physicians for opioid products, 2013\u20132015","volume":"107","author":"Hadland","year":"2017","journal-title":"Am J Public Health"},{"issue":"17","key":"10.1016\/j.jchf.2024.11.020_bib15","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1001\/jama.2017.4455","article-title":"Reconsidering physician\u2013pharmaceutical industry relationships","volume":"317","author":"DeJong","year":"2017","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.jchf.2024.11.020_bib16","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.jchf.2024.11.020_bib18","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2024.11.020_bib20","unstructured":"Economic Research Service. Rural-Urban Commuting Area Codes. U.S. Department of Agriculture. Accessed September 20, 2023. https:\/\/www.ers.usda.gov\/data-products\/rural-urban-commuting-area-codes\/"},{"issue":"11","key":"10.1016\/j.jchf.2024.11.020_bib21","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.008351","article-title":"Diuretic changes, health care resource utilization, and clinical outcomes for heart failure with reduced ejection fraction: from the Change the Management of Patients With Heart Failure Registry","volume":"14","author":"Khan","year":"2021","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10.1016\/j.jchf.2024.11.020_bib22","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/1536867X1201200209","article-title":"Using the margins command to estimate and interpret adjusted predictions and marginal effects","volume":"12","author":"Williams","year":"2012","journal-title":"Stata J"},{"key":"10.1016\/j.jchf.2024.11.020_bib23","author":"Murayama"},{"issue":"11","key":"10.1016\/j.jchf.2024.11.020_bib24","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1007\/s11606-023-08101-x","article-title":"Association of device industry payments, physician supply, and regional utilization of orthopedic and cardiac procedures","volume":"38","author":"Muluk","year":"2023","journal-title":"J Gen Intern Med"},{"issue":"12","key":"10.1016\/j.jchf.2024.11.020_bib25","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.005016","article-title":"Industry payments to cardiologists","volume":"11","author":"Annapureddy","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jchf.2024.11.020_bib26","unstructured":"Persuading the prescribers: pharmaceutical industry marketing and its influence on physicians and patients. The Pew Charitable Trusts. Accessed January 20, 2024. http:\/\/www.Pewtrusts.Org\/En\/Research-and-Analysis\/Fact-Sheets\/2013\/11\/11\/Persuading-the-Prescribers-Pharmaceutical-Industry-Marketing-and-Its-Influence-on-Physicians-and-Patients"},{"issue":"8","key":"10.1016\/j.jchf.2024.11.020_bib27","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1001\/jamacardio.2019.2223","article-title":"Assessment of national coverage and out-of-pocket costs for sacubitril\/valsartan under Medicare Part D","volume":"4","author":"DeJong","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"25","key":"10.1016\/j.jchf.2024.11.020_bib28","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1016\/j.jacc.2022.04.031","article-title":"Medicare coverage and out-of-pocket costs of quadruple drug therapy for heart failure","volume":"79","author":"Faridi","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jchf.2024.11.020_bib29","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1001\/jama.2016.16036","article-title":"Academic detailing: \u201cmarketing\u201d the best evidence to clinicians","volume":"317","author":"Avorn","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2024.11.020_bib30","unstructured":"Price Guide. Drugs.com. Accessed March 2, 2025. https:\/\/www.drugs.com\/price-guide\/"},{"issue":"12","key":"10.1016\/j.jchf.2024.11.020_bib31","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1001\/jamainternmed.2020.2922","article-title":"Out-of-pocket costs for novel guideline-directed diabetes therapies under Medicare Part D","volume":"180","author":"DeJong","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"22","key":"10.1016\/j.jchf.2024.11.020_bib32","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1001\/jama.2020.21395","article-title":"Improving care for heart failure with reduced ejection fraction-a potential polypill-based strategy","volume":"324","author":"Agarwal","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jchf.2024.11.020_bib33","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/CIRCULATIONAHA.122.059661","article-title":"Should polypills be used for heart failure with reduced ejection fraction?","volume":"146","author":"Pandey","year":"2022","journal-title":"Circulation"},{"issue":"13_Supplement","key":"10.1016\/j.jchf.2024.11.020_bib34","article-title":"Patient and provider perspectives on a polypill for heart failure with reduced ejection fraction","volume":"83","author":"Chen","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.jchf.2024.11.020_bib35","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1161\/CIRCULATIONAHA.120.053291","article-title":"The affordability of guideline-directed medical therapy","volume":"143","author":"Sandhu","year":"2021","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.jchf.2024.11.020_bib36","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jacc.2023.02.005","article-title":"Cluster-randomized trial comparing ambulatory decision support tools to improve heart failure care","volume":"81","author":"Mukhopadhyay","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.jchf.2024.11.020_bib37","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.cardfail.2023.03.012","article-title":"Pharmacist- and nurse-led medical optimization in heart failure: a systematic review and meta-analysis","volume":"29","author":"Zheng","year":"2023","journal-title":"J Card Fail"},{"issue":"5","key":"10.1016\/j.jchf.2024.11.020_bib38","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1161\/CIRCULATIONAHA.120.051863","article-title":"An electronically delivered patient-activation tool for intensification of medications for chronic heart failure with reduced ejection fraction","volume":"143","author":"Allen","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.11.020_bib39","unstructured":"Kansteiner F. Novartis takes entresto generic fight to FDA-again-after similar appeal flopped in April. Accessed January 22, 2024. https:\/\/www.fiercepharma.com\/pharma\/novartis-takes-entresto-generic-fight-fda-again-after-similar-appeal-flopped-april"},{"key":"10.1016\/j.jchf.2024.11.020_bib40","unstructured":"FDA moves generic dapagliflozin a step closer to US sales. Medscape. Accessed January 22, 2024. https:\/\/www.medscape.com\/viewarticle\/969050"},{"issue":"21","key":"10.1016\/j.jchf.2024.11.020_bib41","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/j.jacc.2023.03.414","article-title":"The inflation reduction act and out-of-pocket drug costs for Medicare beneficiaries with cardiovascular disease","volume":"81","author":"Kazi","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jchf.2024.11.020_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2022-000219","article-title":"Changes in industry marketing payments to physicians during the COVID-19 pandemic: quasi experimental, difference-in-difference study","volume":"1","author":"Inoue","year":"2022","journal-title":"BMJ Med"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177925000770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177925000770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T04:22:54Z","timestamp":1782966174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177925000770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2213177925000770"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2024.11.020","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct-to-Physician Marketing and Uptake of Optimal Medical Therapy for Heart Failure With Reduced Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2024.11.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}],"article-number":"102380"}}